US clears breakthrough gene therapy for childhood leukemia – ABC News
Los Angeles Times |
US clears breakthrough gene therapy for childhood leukemia
ABC News The Food and Drug Administration calls the approval historic, the first gene therapy to hit the U.S. market. Made from scratch for every patient, it’s one of a wave of “living drugs” under development to fight additional blood cancers and other tumors … Hailing a breakthrough in fighting cancer, FDA approves gene therapy that functions as a ‘living drug’Los Angeles Times FDA Approves Groundbreaking Gene Therapy for CancerMIT Technology Review FDA Approves First Gene Therapy For LeukemiaNPR FDA.gov –CNN all 194 news articles » |
Patch.com |
Harvey Haunts Family • Leukemia Gene Therapy • Massimino Dies: Patch Morning Briefing
Patch.com … Therapy Treatment For Childhood Leukemia. The Food and Drug Administration on Wednesday signed off on the first gene therapy treatment in the U.S. that doctors say uses a patient’s own cells to seek out and destroy deadly childhood leukemia. (Patch … |
|
Breakthrough gene therapy cleared for childhood leukemia
Youngstown Vindicator The Food and Drug Administration called the approval historic, the first gene therapy to hit the U.S. market. Made from scratch for every patient, it’s one of a wave of “living drugs” under development to fight additional blood cancers and other tumors … |
MIT Technology Review |
In a Sign of Gene-Editing Frenzy, Startup Pitches Editing without CRISPR
MIT Technology Review So far, CRISPR is the most versatile gene-editing system known. To edit a genome, it relies on a nuclease—a protein enzyme that slices through the DNA double helix. That damage sets off emergency repairs inside a cell that scientists can harness to … Experts explain the ‘CRISPR‘ practice: A controversial gene editing technologyThe Daily Orange |
|
FDA Oks Genentech’ Actemra To Treat CAR T Cell-Induced Cytokine Release Syndrome
Markets Insider (RTTNews) – Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Actemra (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or … |